Intangia provides a decision‑support platform that continuously ingests scientific, clinical, patent, and market data into a unified evidence graph and uses a momentum detection engine to prioritize target‑indication‑modality opportunities. The system generates explainable, governance‑ready artifacts such as prioritization matrices and freedom‑to‑operate reports, helping pharma and biotech R&D teams allocate capital with lower risk.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharma R&D teams must synthesize fragmented scientific, clinical, patent, and market data to make target, indication, and modality decisions, but existing tools only retrieve information without providing actionable decision support, leading to strategic failures and wasted capital.
Solution
Intangia offers a reasoning layer that continuously ingests and structures evidence from literature, patents, trials, market signals, and optional internal data. Its translation engine detects emerging momentum and maps translational pathways, turning raw signals into prioritized target‑indication‑modality scores. The platform generates explainable decision artifacts—such as momentum intelligence reports, prioritization matrices, and freedom‑to‑operate outputs—ready for portfolio governance and investment committees. By unifying evidence and providing traceable, evidence‑linked decision trails, Intangia enables faster, lower‑risk capital allocation and more confident go/kill/resize choices.
Target Audience
Primary users are R&D strategy and portfolio management teams within pharmaceutical and biotech companies that need evidence‑driven prioritization of targets, indications, and modalities.
Features
- Continuous ingestion of scientific, clinical, patent, company, deal, and investment data into a unified evidence graph
- Momentum detection engine that identifies non‑obvious surges in evidence and validates signals against matched controls
- Translational pathway analysis that maps emerging mechanisms to potential indications before consensus forms
- Automated generation of governance‑ready decision artifacts (prioritization matrices, FTO reports, momentum intelligence)
- Explainable rationale layer that links each recommendation to its underlying evidence for auditability
- Support for capital actions including target selection, asset repurposing, indication expansion, and partnership screening